Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
20 studies found for:    "Anemia, Hemolytic, Autoimmune"
Show Display Options
Rank Status Study
1 Completed Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia
Condition: Anemia, Hemolytic, Autoimmune
Interventions: Drug: prednisolone + mabthera;   Drug: Prednisolone
2 Recruiting A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
Condition: Warm Antibody Autoimmune Hemolytic Anemia
Interventions: Drug: Fostamatinib 150 mg bid;   Drug: Fostamatinib 100 mg bid
3 Recruiting Immunopathology of Autoimmune Hemolytic Anemia
Condition: Autoimmune Hemolytic Anemia
Intervention: Biological: blood samples
4 Recruiting Study the Role of T Lymphocytes in Autoimmune Hemolytic Anemia
Condition: Autoimmune Hemolytic Anemia
Intervention: Biological: blood sample
5 Active, not recruiting Rituximab in Auto-Immune Hemolytic Anemia
Condition: Warm Autoimmune Hemolytic Anemia
Interventions: Drug: rituximab (Mabthera®);   Drug: Placebo
6 Not yet recruiting Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
Condition: Autoimmune Hemolytic Anemia
Intervention: Drug: Interleukine-2
7 Unknown  Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.
Conditions: Anemia;   Anemia, Hemolytic;   Anemia, Hemolytic, Autoimmune;   Hemolysis;   Hematologic Diseases;   Autoimmune Diseases;   Immune System Diseases;   Pathologic Processes
Interventions: Drug: levamisole;   Drug: Prednisone
8 Completed Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
Conditions: Idiopathic Thrombocytopenic Purpura;   Anemia, Hemolytic, Autoimmune
Intervention: Drug: Alemtuzumab, Rituximab
9 Completed A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia
Condition: Autoimmune Hemolytic Disease (Cold Type) (Warm Type)
Intervention: Drug: prednisone, low dose rituximab
10 Recruiting Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
Conditions: Cold Agglutinin Disease;   Autoimmune Hemolytic Anemia
Intervention: Drug: Bendamustine, Rituximab
11 Completed Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate
12 Completed Treatment of Autoimmune Thrombocytopenia (AITP)
Conditions: Autoimmune Disease;   Autoimmune Hemolytic Anemia;   Thrombocytopenia
Intervention: Device: Isolex 300i
13 Completed Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
Conditions: Anemia, Hemolytic, Autoimmune;   Felty Syndrome;   Purpura, Thrombocytopenic;   Autoimmune Diseases
Interventions: Drug: cyclophosphamide;   Drug: filgrastim
14 Active, not recruiting Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease
Condition: Refractory Cold Agglutinin Disease
Intervention: Drug: Bortezomib
15 Completed Therapy of Chronic Cold Agglutinin Disease With Eculizumab
Condition: Cold Agglutinin Disease
Intervention: Drug: Eculizumab
16 Completed Therapy for Chronic Cold Agglutinin Disease
Condition: Cold Agglutinin Disease
Interventions: Drug: Rituximab;   Drug: Fludarabine
17 Recruiting Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement Mediated Disorders
Conditions: Bullous Pemphigoid (BP);   Cold Agglutinin Disease;   Warm Autoimmune Hemolytic Anemia;   End-stage Renal Disease (ESRD)
Interventions: Drug: TNT009;   Other: Placebo
18 Unknown  Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
Conditions: Purpura, Schoenlein-Henoch;   Graft Versus Host Disease;   Anemia, Hemolytic, Autoimmune;   Rheumatoid Arthritis;   Churg-Strauss Syndrome;   Hypersensitivity Vasculitis;   Wegener's Granulomatosis;   Systemic Lupus Erythematosus;   Giant Cell Arteritis;   Pure Red Cell Aplasia;   Juvenile Rheumatoid Arthritis;   Polyarteritis Nodosa;   Autoimmune Thrombocytopenic Purpura;   Takayasu Arteritis
Interventions: Drug: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: filgrastim;   Drug: methylprednisolone;   Drug: prednisone;   Procedure: Autologous Peripheral Blood Stem Cell Transplantation
19 Completed The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
Conditions: Pemphigus;   Auto-immune Thrombocytopenic Purpura;   Hemolytic Auto-immune Anaemia;   Cold Agglutinin Disease;   Cryoglobulinemia
Intervention: Drug: Rituximab (MABTHERA® or RITUXAN®).
20 Active, not recruiting Sirolimus for Autoimmune Disease of Blood Cells
Conditions: Autoimmune Pancytopenia;   Autoimmune Lymphoproliferative Syndrome (ALPS);   Evans Syndrome;   Idiopathic Thrombocytopenic Purpura;   Anemia, Hemolytic, Autoimmune;   Autoimmune Neutropenia;   Lupus Erythematosus, Systemic;   Inflammatory Bowel Disease;   Rheumatoid Arthritis
Intervention: Drug: sirolimus

Study has passed its completion date and status has not been verified in more than two years.